333 related articles for article (PubMed ID: 27879448)
1. RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
Shenkar R; Shi C; Austin C; Moore T; Lightle R; Cao Y; Zhang L; Wu M; Zeineddine HA; Girard R; McDonald DA; Rorrer A; Gallione C; Pytel P; Liao JK; Marchuk DA; Awad IA
Stroke; 2017 Jan; 48(1):187-194. PubMed ID: 27879448
[TBL] [Abstract][Full Text] [Related]
2. Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease.
Shenkar R; Peiper A; Pardo H; Moore T; Lightle R; Girard R; Hobson N; Polster SP; Koskimäki J; Zhang D; Lyne SB; Cao Y; Chaudagar K; Saadat L; Gallione C; Pytel P; Liao JK; Marchuk D; Awad IA
Stroke; 2019 Mar; 50(3):738-744. PubMed ID: 30744543
[TBL] [Abstract][Full Text] [Related]
3. Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease.
McDonald DA; Shi C; Shenkar R; Stockton RA; Liu F; Ginsberg MH; Marchuk DA; Awad IA
Stroke; 2012 Feb; 43(2):571-4. PubMed ID: 22034008
[TBL] [Abstract][Full Text] [Related]
4. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.
Stockton RA; Shenkar R; Awad IA; Ginsberg MH
J Exp Med; 2010 Apr; 207(4):881-96. PubMed ID: 20308363
[TBL] [Abstract][Full Text] [Related]
5. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
Kolavennu V; Zeng L; Peng H; Wang Y; Danesh FR
Diabetes; 2008 Mar; 57(3):714-23. PubMed ID: 18083785
[TBL] [Abstract][Full Text] [Related]
6. Role of Rho Kinase Inhibition in the Protective Effect of Fasudil and Simvastatin Against 3-Nitropropionic Acid-Induced Striatal Neurodegeneration and Mitochondrial Dysfunction in Rats.
Ahmed LA; Darwish HA; Abdelsalam RM; Amin HA
Mol Neurobiol; 2016 Aug; 53(6):3927-3938. PubMed ID: 26169112
[TBL] [Abstract][Full Text] [Related]
7. Rho kinase inhibition by fasudil has anti-inflammatory effects in hypercholesterolemic rats.
Ma Z; Zhang J; Du R; Ji E; Chu L
Biol Pharm Bull; 2011; 34(11):1684-9. PubMed ID: 22040880
[TBL] [Abstract][Full Text] [Related]
8. The Rho kinase inhibitor, fasudil, ameliorates diabetes-induced cardiac dysfunction by improving calcium clearance and actin remodeling.
Lai D; Gao J; Bi X; He H; Shi X; Weng S; Chen Y; Yang Y; Ye Y; Fu G
J Mol Med (Berl); 2017 Feb; 95(2):155-165. PubMed ID: 27576917
[TBL] [Abstract][Full Text] [Related]
9. A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease.
McDonald DA; Shenkar R; Shi C; Stockton RA; Akers AL; Kucherlapati MH; Kucherlapati R; Brainer J; Ginsberg MH; Awad IA; Marchuk DA
Hum Mol Genet; 2011 Jan; 20(2):211-22. PubMed ID: 20940147
[TBL] [Abstract][Full Text] [Related]
10. B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models.
Shi C; Shenkar R; Zeineddine HA; Girard R; Fam MD; Austin C; Moore T; Lightle R; Zhang L; Wu M; Cao Y; Gunel M; Louvi A; Rorrer A; Gallione C; Marchuk DA; Awad IA
J Neuroimmune Pharmacol; 2016 Jun; 11(2):369-77. PubMed ID: 27086141
[TBL] [Abstract][Full Text] [Related]
11. RhoA and Rho-kinase inhibitors modulate cervical resistance: The possible role of RhoA/Rho-kinase signalling pathway in cervical ripening and contractility.
Domokos D; Ducza E; Gáspár R
Eur J Pharmacol; 2019 Jan; 843():27-33. PubMed ID: 30445018
[TBL] [Abstract][Full Text] [Related]
12. Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.
Shenkar R; Shi C; Rebeiz T; Stockton RA; McDonald DA; Mikati AG; Zhang L; Austin C; Akers AL; Gallione CJ; Rorrer A; Gunel M; Min W; De Souza JM; Lee C; Marchuk DA; Awad IA
Genet Med; 2015 Mar; 17(3):188-196. PubMed ID: 25122144
[TBL] [Abstract][Full Text] [Related]
13. A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease.
McKerracher L; Shenkar R; Abbinanti M; Cao Y; Peiper A; Liao JK; Lightle R; Moore T; Hobson N; Gallione C; Ruschel J; Koskimäki J; Girard R; Rosen K; Marchuk DA; Awad IA
Transl Stroke Res; 2020 Jun; 11(3):365-376. PubMed ID: 31446620
[TBL] [Abstract][Full Text] [Related]
14. Novel Murine Models of Cerebral Cavernous Malformations.
Detter MR; Shenkar R; Benavides CR; Neilson CA; Moore T; Lightle R; Hobson N; Shen L; Cao Y; Girard R; Zhang D; Griffin E; Gallione CJ; Awad IA; Marchuk DA
Angiogenesis; 2020 Nov; 23(4):651-666. PubMed ID: 32710309
[TBL] [Abstract][Full Text] [Related]
15. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype.
Borikova AL; Dibble CF; Sciaky N; Welch CM; Abell AN; Bencharit S; Johnson GL
J Biol Chem; 2010 Apr; 285(16):11760-4. PubMed ID: 20181950
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator.
Lapchak PA; Han MK
Brain Res; 2010 Jul; 1344():217-25. PubMed ID: 20493175
[TBL] [Abstract][Full Text] [Related]
17. FSD-C10: A more promising novel ROCK inhibitor than Fasudil for treatment of CNS autoimmunity.
Xin YL; Yu JZ; Yang XW; Liu CY; Li YH; Feng L; Chai Z; Yang WF; Wang Q; Jiang WJ; Zhang GX; Xiao BG; Ma CG
Biosci Rep; 2015 Jul; 35(5):. PubMed ID: 26223433
[TBL] [Abstract][Full Text] [Related]
18. Novel Chronic Mouse Model of Cerebral Cavernous Malformations.
Cardoso C; Arnould M; De Luca C; Otten C; Abdelilah-Seyfried S; Heredia A; Leutenegger AL; Schwaninger M; Tournier-Lasserve E; Boulday G
Stroke; 2020 Apr; 51(4):1272-1278. PubMed ID: 31992178
[TBL] [Abstract][Full Text] [Related]
19. Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK.
Miyamoto C; Maehata Y; Ozawa S; Ikoma T; Kubota E; Izukuri K; Kato Y; Hata R; Lee MC
J Pharmacol Sci; 2012; 120(3):241-9. PubMed ID: 23099322
[TBL] [Abstract][Full Text] [Related]
20. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice.
Stirzaker RA; Biswas PS; Gupta S; Song L; Bhagat G; Pernis AB
Lupus; 2012 May; 21(6):656-61. PubMed ID: 22345122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
